Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome

doi:10.19871/j.cnki.xfcrbzz.2022.01.017

Abstract

Abstract: In 2017, the AIDS Group of Infectious Diseases Branch of the Chinese Medical Association and the AIDS Group of tropical Diseases and Parasitology of the Chinese Medical Association jointly formulated and issued the first edition of the expert consensus on the diagnosis and treatment of HIV combined with Mycobacterium tuberculosis infection. In 2021, Professional Committee of HIV Combined with TB, Chinese Association of STD and AIDS Prevention and Control revised and updated the first version of the consensus. The new consensus has updated the tuberculosis prophylaxis treatment in HIV/AIDS patients, the molecular diagnosis of tuberculosis, the treatment of drug-resistant tuberculosis, the timing and regimen of antiretroviral therapy, the diagnosis and treatment of tuberculosis-related immune reconstitution inflammatory syndrome, and management of side effects. This consensus will be updated regularly based on the latest clinical research evidence.

Key words: Human immunodeficiency virus, Acquired immunodeficiency syndrome, Mycobacterium tuberculosis infection, Diagnosis, Treatment, Expert consensus

Professional Committee of HIV Combined with TB, Chinese Association of STD, AIDS Prevention, Control. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(1): 73-87.

References

[1] Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health,the HIV Medicine Association of the Infectious Diseases Society of America[EB/OL].(2021-08-18)[2021-11-05]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf.
[2] The American Thoracic Society (ATS) andthe Centers for Disease Control and Prevention (CDC).Targeted tuberculin testing and treatment of latent tuberculosis infection[J]. MMWR Recomm Rep, 2000, 49(RR-6):1-51.
[3] HORSBURGH CR JR.Priorities for the treatment of latent tuberculosis infection in the United States[J]. N Engl J Med, 2004, 350(20):2060-2067.
[4] DAY JH, GRANT AD, FIELDING KL, et al.Does tuberculosis increase HIV load?[J]. J Infect Dis, 2004, 190(9):1677-1684.
[5] LÓPEZ-GATELL H, COLE SR, MARGOLICK JB, et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence[J]. AIDS, 2008, 22(14):1869-1873.
[6] WORLD HEALTH ORGANIZATION. Global tuberculosis report2021[M/OL]. Geneva: World Health Organization; 2021.(2021-10-14)[2021-11-05]. https://www.who.int/publications/i/item/9789240037021.
[7] GAO J, ZHENG P, FU H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis[J/OL]. PLoS One, 2013, 8(5): e64915. (2013-05-31)[2021-11-05]. https://doi.org/10.1371/journal.pone.0064915.
[8] SHEN Y, LU H.Prevalence and predictors of tuberculosis among adults with newly diagnosed HIV/AIDS[J/OL]. Int J Infect Dis, 2016, 45 (Supplement 1): 412.(2016-04-01)[2021-11-05]. https://doi.org/10.1016/j.ijid.2016.02.879.
[9] LIU E, WANG Q, ZHANG G, et al.Tuberculosis/HIV coinfection and treatment trends - China, 2015-2019[J]. China CDC Wkly, 2020, 2(48):924-928.
[10] BELL LCK, NOURSADEGHI M.Pathogenesis of HIV-1 and mycobacterium tuberculosis co-infection[J]. Nat Rev Microbiol, 2018, 16(2): 80-90.
[11] 沈银忠,卢洪洲. 艾滋病合并结核病诊治现状[J]. 中国实用内科杂志,2015, 35(8):671-674.
[12] GUPTA RK, LUCAS SB, FIELDING KL, et al.Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis[J]. AIDS, 2015, 29(15):1987-2002.
[13] MESFIN YM, HAILEMARIAM D, BIADGILIGN S, et al.Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis [J/OL]. PLoS One, 2014, 9(1): e82235.
[14] SINGH A, PRASAD R, BALASUBRAMANIAN V, et al.Drug-resistant tuberculosis and HIV infection: current perspectives[J]. HIV/AIDS (Auckland, N.Z.), 2020, 12: 9-31.
[15] GANDHI NR, SHAH NS, ANDREWS JR, et al.HIV co-infection in multidrug-and extensively drug-resistant tuberculosis Result in high early mortality[J]. Am J Respir Crit Care Med, 2010, 181(1): 80-86.
[16] 中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识[J]. 中华临床感染病杂志, 2017, 10(2): 81-90.
[17] WORLD HEALTH ORGANIZATION. WHO operational handbook on tuberculosis. Module 1-Prevention: tuberculosis preventive treatment [M/OL]. Geneva, World Health Organization.2020. [2021-11-05].https://apps.who.int/iris/bitstream/handle/10665/331525/9789240002906-eng.pdf.
[18] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV[EB/OL]. Department of Health and Human Services. (2021-10-04) [2021-11-05]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
[19] DOOLEY KE, CHURCHYARD G, SAVIC RM, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir[C/OL]. Seattle, Washington, USA; 2019 (2019-04-25) [2021-11-05]. http://www.croiconference.org/sessions/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir.
[20] WORLD HEALTH ORGANIZATION. WHO operational handbook on tuberculosis. Module 2: Screening - Systematic screening for tuberculosis disease[M/OL]. Geneva, World Health Organization.2021. [2021-11-05].https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf.
[21] HANIFA Y, FIELDING KL, CHIHOTA VN, et al. A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa[J/OL]. PLoS One, 2017, 12(8): e0181519. (2017-08-03)[2021-11-05]. https://doi.org/10.1371/journal.pone.0181519
[22] WORLD HEALTH ORGANIZATION. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detention, 2021 update[M/OL]. Geneva: World Health Organization; 2021. [2021-11-05].https://www.who.int/publications/i/item/9789240030589.
[23] 乐晓琴, 陈军, 沈银忠, 等. 结核分枝杆菌/利福平耐药实时荧光定量核酸扩增检测技术诊断艾滋病患者肺结核的临床应用评[J]. 中华传染病杂志, 2021, 39(1): 21-24.
[24] WORLD HEALTH ORGANIZATION. Update on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication[EB/OL]. Geneva: World Health Organization, 2021[2021-11-05]. https://apps.who.int/iris/handle/10665/339611.
[25] ELLIOTT AM, HALWIINDI B, HAYES RJ, et al.The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia[J]. J Trop Med Hyg, 1993, 96(1):1-11.
[26] NAHID P, DORMAN SE, ALIPANAH N, et al.Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis[J]. Clin Infect Dis, 2016, 63(7):e147-e195.
[27] SHRINER KA, MATHISEN GE, GOETZ MB.Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls[J]. Clin Infect Dis, 1992, 15(4):601-605.
[28] JONES BE, YOUNG SM, ANTONISKIS D, et al.Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection[J]. Am Rev Respir Dis, 1993, 148(5):1292-1297.
[29] SHAFER RW, KIM DS, WEISS JP, et, al. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection[J]. Medicine (Baltimore), 1991, 70(6):384-397.
[30] CHEN J, SUN J, ZHANG R, et al.T-SPOT.TB in the diagnosis of active tuberculosis among HIV-infected patients with advanced immunodeficiency[J]. AIDS Res Hum Retroviruses, 2011, 27(3):289-294.
[31] CAI R, CHEN J, GUAN L, et al.Relationship between T-SPOT.TB responses and numbers of circulating CD4+ T-cells in HIV infected patients with active tuberculosis[J]. Biosci Trends, 2014, 8(3):163-168.
[32] HORSBURGH CR, JR, BARRY CE 3RD, LANGE C. Treatment of Tuberculosis[J]. N Engl J Med, 2015, 373(22):2149-2160.
[33] WORLD HEALTH ORGANIZATION. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment2020[M/OL]. Geneva: World Health Organization(2021-06-15) [2021-11-05]. https://www.who.int/publications-detail-redirect/9789240006997.
[34] DORMAN SE, NAHID P, KURBATOVA EV, et al.Four-month rifapentine regimens with or without moxifloxacin for tuberculosis[J]. N Engl J Med, 2021, 384(18): 1705-1718.
[35] WORLD HEALTH ORGANIZATION. Treatment of drug-susceptible tuberculosis: rapid communication[M/OL]. Geneva: World Health Organization(2021-06-14) [2021-11-05].https://www.who.int/publications/i/item/9789240028678.
[36] WORLD HEALTH ORGANIZATION. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach[M/OL]. Geneva: World Health Organization, 2021.(2021-07-16) [2021-11-05]. https://www.who.int/publications/i/item/9789240031593.
[37] 中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10): 1025-1073.
[38] 中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(10): 733-749.
[39] WORLD HEALTH ORGANIZATION. Guidelines for treatment of drug-susceptible tuberculosis and patient care [EB/OL]. (2021-10-04) [2021-11-05]. https://www.who.int/publications/i/item/9789241550000.
[40] LOVEDAY M, HUGHES J, SUNKARI B, et al.Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa[J]. Clin Infect Dis, 2021, 72(7):1158-1168.
[41] THWAITES GE, NGUYEN DB, NGUYEN HD, et al.Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults[J]. N Engl J Med, 2004, 351(17):1741-1751.
[42] SHU Y, DENG Z, WANG H, et al.Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials[J]. AIDS Res Ther, 2021, 18(1):25.
[43] DOOLEY KE, KAPLAN R, MWELASE N, et al.Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial[J]. Clin Infect Dis, 2020, 70(4):549-556.
[44] DE CASTRO N, MARCY O, CHAZALLON C, et al.Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial[J]. Lancet Infect Dis, 2021, 21(6): 813-822.
[45] NAMALE PE, ABDULLAHI LH, FINE S, et al.Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis[J]. Future Microbiol, 2015, 10(6):1077-1099.
[46] MEINTJES G, STEK C, BLUMENTHAL L, et al.Prednisone for the prevention of paradoxical tuberculosis-associated IRIS[J]. N Engl J Med, 2018, 379(20):1915-1925.
[47] WILSON JW, NILSEN DM, MARKS SM.Multidrug-resistant tuberculosis in patients with human immunodeficiency virus. Management considerations within high-resourced settings[J]. Ann Am Thorac Soc, 2020, 17(1):16-23.
[48] MONEDERO-RECUERO I, HERNANDO-MARRUPE L, SÁNCHEZ-MONTALVÁ A, et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment[J]. Int J Tuberc Lung Dis, 2018, 12(12): 1411-1421.